82 related articles for article (PubMed ID: 20664961)
1. The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.
Lenart M; Trzyna E; Rutkowska M; Bukowska-Strakova K; Szaflarska A; Pituch-Noworolska A; Szczepanik A; Zembala M; Siedlar M
Int J Mol Med; 2010 Sep; 26(3):435-42. PubMed ID: 20664961
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
4. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
de Haas M; Koene HR; Kleijer M; de Vries E; Simsek S; van Tol MJ; Roos D; von dem Borne AE
J Immunol; 1996 Apr; 156(8):2948-55. PubMed ID: 8609432
[TBL] [Abstract][Full Text] [Related]
5. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
Koene HR; Kleijer M; Algra J; Roos D; von dem Borne AE; de Haas M
Blood; 1997 Aug; 90(3):1109-14. PubMed ID: 9242542
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.
Böttcher S; Ritgen M; Brüggemann M; Raff T; Lüschen S; Humpe A; Kneba M; Pott C
J Immunol Methods; 2005 Nov; 306(1-2):128-36. PubMed ID: 16181633
[TBL] [Abstract][Full Text] [Related]
7. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections.
de Vries E; Koene HR; Vossen JM; Gratama JW; von dem Borne AE; Waaijer JL; Haraldsson A; de Haas M; van Tol MJ
Blood; 1996 Oct; 88(8):3022-7. PubMed ID: 8874200
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
9. [Fcγ receptorIIIa polymorphism in healthy children and those with hematological malignancies].
Qu YH; Li Y; Wu YF; Fang JP; Wei J; Huang SL; Ma XX; Huang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):959-62. PubMed ID: 20723308
[TBL] [Abstract][Full Text] [Related]
10. Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.
Ozturk C; Aksu G; Berdeli A; Kutukculer N
Clin Exp Med; 2006 Mar; 6(1):27-32. PubMed ID: 16550341
[TBL] [Abstract][Full Text] [Related]
11. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.
Congy-Jolivet N; Bolzec A; Ternant D; Ohresser M; Watier H; Thibault G
Cancer Res; 2008 Feb; 68(4):976-80. PubMed ID: 18281470
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
[TBL] [Abstract][Full Text] [Related]
13. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing.
Mota G; Moldovan I; Calugaru A; Hirt M; Kozma E; Galatiuc C; Brasoveanu L; Boltz-Nitulescu G
Scand J Immunol; 2004 Mar; 59(3):278-84. PubMed ID: 15030579
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies.
Galatiuc C; Gherman M; Metes D; Sulica A; DeLeo A; Whiteside TL; Herberman RB
Cell Immunol; 1995 Jul; 163(2):167-77. PubMed ID: 7606790
[TBL] [Abstract][Full Text] [Related]
15. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II).
Jawahar S; Moody C; Chan M; Finberg R; Geha R; Chatila T
Clin Exp Immunol; 1996 Mar; 103(3):408-13. PubMed ID: 8608639
[TBL] [Abstract][Full Text] [Related]
17. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.
Edberg JC; Langefeld CD; Wu J; Moser KL; Kaufman KM; Kelly J; Bansal V; Brown WM; Salmon JE; Rich SS; Harley JB; Kimberly RP
Arthritis Rheum; 2002 Aug; 46(8):2132-40. PubMed ID: 12209518
[TBL] [Abstract][Full Text] [Related]
18. Relevance of the low-affinity type of the Fcgamma-receptor IIIa-polymorphism in bullous pemphigoid.
Weisenseel P; Martin S; Partscht K; Messer G; Prinz JC
Arch Dermatol Res; 2007 Jun; 299(3):163-4. PubMed ID: 17457599
[TBL] [Abstract][Full Text] [Related]
19. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
[TBL] [Abstract][Full Text] [Related]
20. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
